Literature DB >> 17449148

Update on non-alcoholic fatty liver disease in children.

Dimitrios Papandreou1, Israel Rousso, Ioannis Mavromichalis.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is probably the most common cause of liver disease in the pediatric community. It is closely associated with obesity and insulin resistance. NAFLD may lead to non-alcoholic steatohepatitis (NASH). Although NASH is a prerequisite for the definition of NAFLD in adults and children, distinct differences are often apparent in the extent or location of fat, inflammation and fibrosis. Confirmation of the diagnosis of NAFLD can usually be achieved by imaging studies; however, staging the disease requires a liver biopsy. Current treatment relies on weight loss and exercise, although various insulin-sensitizing agents, antioxidants and medications appear promising. The aim of this review is to summarize what is known about pediatric NAFLD in terms of prevalence, pathogenesis, diagnosis, histology and treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17449148     DOI: 10.1016/j.clnu.2007.02.002

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  55 in total

1.  Experimental evidence for therapeutic potential of taurine in the treatment of nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Angela M Nivala; Jon C Gonzales; Kyle T Pfaffenbach; Dong Wang; Yuren Wei; Hua Jiang; David J Orlicky; Dennis R Petersen; Michael J Pagliassotti; Kenneth N Maclean
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-09-28       Impact factor: 3.619

2.  Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology.

Authors:  Yoshihisa Takahashi; Toshio Fukusato
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

3.  Physical Activity is Related to Fatty Liver Marker in Obese Youth, Independently of Central Obesity or Cardiorespiratory Fitness.

Authors:  Clarice Martins; Luisa Aires; Ismael Freitas Júnior; Gustavo Silva; Alexandre Silva; Luís Lemos; Jorge Mota
Journal:  J Sports Sci Med       Date:  2015-03-01       Impact factor: 2.988

Review 4.  Brain metabolic dysfunction at the core of Alzheimer's disease.

Authors:  Suzanne M de la Monte; Ming Tong
Journal:  Biochem Pharmacol       Date:  2013-12-28       Impact factor: 5.858

Review 5.  Non-alcoholic fatty liver disease: The diagnosis and management.

Authors:  Shehab M Abd El-Kader; Eman M Salah El-Den Ashmawy
Journal:  World J Hepatol       Date:  2015-04-28

Review 6.  Dietary habits and behaviors associated with nonalcoholic fatty liver disease.

Authors:  Kenichiro Yasutake; Motoyuki Kohjima; Kazuhiro Kotoh; Manabu Nakashima; Makoto Nakamuta; Munechika Enjoji
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 7.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

8.  Growth Trajectories of Refugee and Nonrefugee Children in the United States.

Authors:  Elizabeth Dawson-Hahn; Suzinne Pak-Gorstein; Jasmine Matheson; Chuan Zhou; Katherine Yun; Kevin Scott; Colleen Payton; Elizabeth Stein; Annette Holland; H Mollie Grow; Jason A Mendoza
Journal:  Pediatrics       Date:  2016-11-10       Impact factor: 7.124

Review 9.  The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease.

Authors:  Christopher L Gentile; Michael J Pagliassotti
Journal:  Curr Opin Investig Drugs       Date:  2008-10

10.  Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.

Authors:  Suzanne M de la Monte; Ming Tong; Margot Lawton; Lisa Longato
Journal:  Mol Neurodegener       Date:  2009-12-24       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.